Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinobufacini perfusion versus TACE for intermediate and advanced hepatoma
ChiCTR-TRC-10001057Phase 2Completed
- Sponsor
- Changhai Hospital of Traditional Chinese Medicine
- Start
- Oct 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cinobufacini and epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Changhai Hospital of Traditional Chinese Medicine. Primary endpoint: Tumor response by RECIST. Started Oct 2010; status: completed.
02
Drugs
cinobufaciniepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-10001057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001057.